Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line durvalumab ± tremelimumab vs chemotherapy in unresectable stage IV urothelial cancer
jRCT2080223100Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Durvalumab monotherapy, Durvalumab + tremelimumab and Standard-of-care chemotherapy (3 arms). Started Feb 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2080223100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223100.